3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
9
Terminated
2
Active not recruiting
2
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
7
Lymphoma, Large B-Cell, Diffuse
6
Osteosarcoma
3
Lymphoma, B-Cell
3
Sarcoma, Ewing
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Penile Neoplasms
2
Neurofibrosarcoma
2
Liposarcoma
2
Hemangiosarcoma
2
Fibrosarcoma
2
Burkitt Lymphoma
2
Wilms Tumor
1
Vascular Neoplasms
1
Teratoma
1
Solitary Fibrous Tumors
1
Smooth Muscle Tumor
1
Sarcoma, Synovial
1
Sarcoma, Endometrial Stromal
1
Sarcoma, Clear Cell
1
Rhabdomyosarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Pleuropulmonary blastoma
1
Neuroblastoma
1
Nerve Sheath Neoplasms
1
Neoplasms, Adipose Tissue
1
Neoplasm Metastasis
1
Myoepithelioma
1
Lymphoma, T-Cell, Peripheral
1
Interventions
Temozolomide
7
Vincristine
6
Cyclophosphamide
5
fludarabine
3
Irinotecan
3
pegfilgrastim
2
irinotecan sucrosofate
2
Zoledronic Acid
2
Vinorelbine
2
Filgrastim
2
Dactinomycin
2
talazoparib
1
silmitasertib
1
regorafenib
1
pegylated granulocyte colony-stimulating factor
1
pazopanib
1
liposomal doxorubicin
1
fludarabine phosphate
1
cabozantinib
1
atezolizumab
1
amino-acid, glucose, and electrolyte solution
1
Whole-Body Irradiation
1
Vorinostat
1
Tacrolimus
1
Radiotherapy
1
Mesna
1
Melphalan
1
Influenza Vaccines
1
Indocyanine Green
1
Immunotherapy, Adoptive
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Rhabdomyosarcoma
×
Ifosfamide
×
Clear all
NCT04625907
2024-05-23
FaR-RMS
University of Birmingham
Phase 1/2
Recruiting
1,672 enrolled